Evolv Technology Reports Record Third Quarter Financial Results

Rhea-AI Summary

Evolv Technology (NASDAQ: EVLV) reported a strong Q3 2022, achieving revenues of $16.5 million, up 96% year-over-year, with an Ending ARR of $28.7 million, a 189% increase. The company raised its 2022 revenue outlook to $46-$48 million, significantly higher than previous estimates. TCV for Q3 reached $45.4 million, a 167% growth from the prior year. Despite this, net loss for Q3 was $(18.6) million. Looking ahead, Evolv expects ARR for 2023 to exceed $65 million, reflecting over 100% growth.

Positive

• Q3 2022 revenue of $16.5 million, up 96% YoY.
• Q3 Ending ARR of $28.7 million, up 189% YoY.
• Raised 2022 revenue outlook to $46-$48 million.
• New customer acquisition included major school districts and hospitals.

Negative

• Q3 2022 net loss of $(18.6) million.
• Losses increased from $(12.9) million YoY.

– Company Raises Outlook for 2022 –

• Q3 Revenue of $16.5 million, up 96% year-over-year
• Q3 Ending ARR of $28.7 million, up 189% year-over-year
• Q3 Ending RPO of $109.4 million, up 220% year-over-year
• Q3 Ending Evolv Express® subscriptions of 1,692, up 198% year-over-year

WALTHAM, Mass.--(BUSINESS WIRE)--

Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced financial results for its third quarter ended September 30, 2022¹ and raised its business outlook for 2022.

“We’re pleased to be reporting record third quarter results which were highlighted by strong growth in revenues and continued market expansion,” said Peter George, President and Chief Executive Officer of Evolv Technology. “We experienced particularly robust market adoption with 92 new customers including five of the largest school districts in the United States, over a dozen new hospitals across the nation, as well as the home stadiums of five additional professional sports teams. Our results and momentum position us well to deliver full year growth above our previous outlook for 2022.”

Results for the Third Quarter of 2022

Total revenue for the third quarter of 2022 was $16.5 million, an increase of 96% compared to $8.4 million for the third quarter of 2021. Total Contract Value (“TCV”)² of orders booked for the third quarter of 2022 was $45.4 million, an increase of 167% compared to $17.0 million in the third quarter of 2021. Annual Recurring Revenue (“ARR”)³ was $28.7 million at the end of third quarter of 2022, an increase of 189% compared to $9.9 million at the end of the third quarter of 2021. Net loss for the third quarter of 2022 was $(18.6) million, or $(0.13) per basic and diluted share, compared to net income attributable to common stockholders for basic and diluted shares of $20.8 million and $21.3 million, respectively, or $0.17 per basic share and $0.14 per diluted share, in the third quarter of 2021. Adjusted earnings (loss)⁴ for the third quarter of 2022 was $(18.6) million, or $(0.13) per diluted share, compared to adjusted earnings (loss)⁴ of $(12.9) million, or $(0.08) per diluted share, for the third quarter of 2021. Adjusted EBITDA⁴ for the third quarter of 2022 was $(18.0) million compared to $(11.5) million in the third quarter of 2021.

Results for the First Nine Months of 2022

Total revenue for the nine months ended September 30, 2022 was $34.3 million, an increase of 104% compared to $16.8 million for the nine months ended September 30, 2021. TCV² of orders booked for the nine months ended September 30, 2022 was $86.6 million, an increase of 141% compared to $35.9 million for the nine months ended September 30, 2021. Net loss for the nine months ended September 30, 2022 was $(58.1) million, or $(0.40) per basic and diluted share, compared to net loss of $(15.7) million, or $(0.33) per basic and diluted share, for the nine months ended September 30, 2021. Adjusted earnings (loss)⁴ for the nine months ended September 30, 2022 was $(54.3) million, or $(0.38) per diluted share, compared to $(33.5) million, or $(0.70) per diluted share, for the nine months ended September 30, 2021. Adjusted EBITDA⁴ for the nine months ended September 30, 2022 was $(51.7) million, compared to $(24.9) million for the nine months ended September 30, 2021.

Company Raises Outlook for 2022

The Company today commented on its business outlook for 2022. The Company's outlook is based on the current indications for its business, which may change at any time.

		2022 Business Outlook
Estimate (In millions)		Issued August 10, 2022		Issued November 9, 2022
Total Revenue		$29-$31		$46-$48
Annual Recurring Revenue3 (ARR) at 12/31		$27-$28		$31-$32
Adjusted EBITDA4		($65-$67)		No change
Cash and Cash Equivalents		$220-$230		No change

“We believe we are well positioned to deliver strong top line growth above our previously issued guidance in 2022,” said Mark Donohue, Chief Financial Officer of Evolv Technology. “Our preliminary estimates for 2023 call for exiting ARR in the range of $65 million and $70 million – reflecting growth of more than 100% – and full year revenues in the range of $55 million to $60 million, reflecting our transition towards a subscription model. We also expect to significantly reduce our full year operating cash usage in 2023. We will provide formal detailed guidance for 2023 when we release results for the fourth quarter of 2022.”

Company to Host Live Conference Call and Webcast

The Company’s management team plans to host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss the financial results as well as management’s outlook for the business and other matters. The conference call may be accessed in the United States by dialing +1.877.692.8955 and using access code 774298. The conference call may be accessed outside of the United States by dialing +1.234.720.6979 and using the same access code. The conference call will be simultaneously webcast on the Company’s investor relations website, which can be accessed at http://ir.evolvtechnology.com. A replay of the conference call will be available for a period of 30 days by dialing +1.866.207.1041 or +1.402.970.0847 and using access code 4430069 or by accessing the webcast replay on the Company’s investor relations website at http://ir.evolvtechnology.com.

About Evolv Technology

Evolv Technology (NASDAQ: EVLV) is transforming human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered weapons detection and analytics. Its mission is to transform security to create a safer world to work, learn, and play. Evolv has digitally transformed the gateways in places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than 425 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category. Evolv Technology®, Evolv Express®, Evolv Insights®, and Evolv Cortex AI® are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit https://evolvtechnology.com.

¹ Amounts herein pertaining to September 30, 2022 represent a preliminary estimate as of the date of this earnings release. More information on our results of operations for the three and nine months ended September 30, 2022 will be provided upon filing our Quarterly Report on Form 10-Q with the Securities and Exchange Commission.

² We define Total Contract Value, or TCV, of orders booked as the total value of the contract over the specified term. Our calculation of TCV is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases). TCV should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of TCV may differ from similarly titled metrics presented by other companies. The fourth quarter of the fiscal year ended December 31, 2022 is the final quarter that we will be reporting TCV.

³ We define Annual Recurring Revenue, or ARR, as subscription revenue and the recurring service revenue related to purchase subscriptions for the final month of the quarter normalized to a one-year period. Our calculation of ARR is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases) that may cause any such contract not to be renewed on its existing terms. In addition, the amount of actual revenue that we recognize over any 12-month period is likely to differ from ARR at the beginning of that period, sometimes significantly. This may occur due to new bookings, cancellations, upgrades, downgrades or other changes in pending renewals, as well as the effects of professional services revenue and acquisitions or divestitures. As a result, ARR should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of ARR may differ from similarly titled metrics presented by other companies.

⁴ Non-GAAP Financial Measures In this press release, the Company’s adjusted operating expenses, adjusted gross profit, adjusted gross margin, adjusted operating income (loss), adjusted EBITDA, adjusted earnings (loss), and adjusted earnings per share-diluted are not presented in accordance with generally accepted accounting principles (GAAP) and are not intended to be used in lieu of GAAP presentations of results of operations. Adjusted gross profit and adjusted gross margin exclude one-time items which management believes provides a more meaningful representation of contribution margin. Adjusted EBITDA is defined as net income (loss) plus depreciation and amortization, share-based compensation, and certain other one-time expenses. Adjusted earnings (loss) is defined as net income (loss) plus stock-based compensation, change in fair value of derivative liability, change in fair value of contingent earn-out liability, change in fair value of contingently issuable common stock liability, change in fair value of public warrant liability, change in fair value of common stock warrant liability, restructuring expenses, loss on impairment of lease equipment, and certain other one-time expenses. Management presents non-GAAP financial measures because it considers them to be important supplemental measures of performance. Management uses non-GAAP financial measures for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and to determine appropriate levels of operating and capital investments. Management also believes non-GAAP financial measures provide additional insight for analysts and investors in evaluating the Company's financial and operational performance. However, non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. We intend to provide non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of non-GAAP financial measures will provide consistency in our financial reporting. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures included in this press release.

Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts should be considered forward-looking statements, including without limitation statements regarding: the transition of our business model, our ability to reduce future cash burn and meet our goals for revenue and profitability, including for fiscal years 2022 and 2023. Forward-looking statements involve the Company’s current expectations and projections relating to its financial condition, competitive position, future financial results, plans, objectives, and business. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “should,” “could,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or the negative of these terms or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect the Company’s current views with respect to future events and the Company’s performance and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation expectations regarding the Company’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures; the Company’s history of losses and lack of profitability; the Company’s reliance on third party contract manufacturing; the rate of innovation required to maintain competitiveness in the markets in which the Company competes; the competitiveness of the market in which the Company competes; the ability for the Company to obtain, maintain, protect and enforce the Company’s intellectual property rights; the concentration of the Company’s revenues on a single solution; the Company’s ability to timely design, produce and launch its solutions, the Company’s ability to invest in growth initiatives and pursue acquisition opportunities; the limited liquidity and trading of the Company’s securities; geopolitical risk and changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; operational risk; risk that the COVID-19 pandemic, including variants, vaccine roll-out efforts, and local, state, and federal responses to addressing the pandemic may have an adverse effect on the Company’s business operations, as well as the Company’s financial condition and results of operations; risks associated with inflation and its possible impact on the Company; litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on resources; and the other important risk factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission ("SEC") on March 28, 2022, as may be updated in other filings we make with the SEC.

These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

EVOLV TECHNOLOGY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
(Unaudited)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Revenue:
Product revenue	$	9,839			$	5,395			$	19,179			$	10,279
Subscription revenue		5,198				2,312				12,208				5,060
Service revenue		1,493				717				2,923				1,456
Total revenue		16,530				8,424				34,310				16,795
Cost of revenue:
Cost of product revenue		12,960				2,967				23,513				7,386
Cost of subscription revenue		2,207				1,277				5,730				3,080
Cost of service revenue		1,138				713				3,392				1,685
Total cost of revenue		16,305				4,957				32,635				12,151
Gross profit		225				3,467				1,675				4,644
Operating expenses:
Research and development		5,616				3,612				13,947				8,399
Sales and marketing		11,746				10,024				33,169				17,756
General and administrative		8,839				7,535				29,268				12,058
Loss from impairment of property and equipment		626				1,656				1,038				1,656
Total operating expenses		26,827				22,827				77,422				39,869
Loss from operations		(26,602	)			(19,360	)			(75,747	)			(35,225	)
Other income (expense), net:
Interest expense		(188	)			(295	)			(489	)			(5,952	)
Interest income		1,052				—				1,611				—
Other expense, net		(57	)			(669	)			(57	)			(669	)
Loss on extinguishment of debt		—				(865	)			—				(12,685	)
Change in fair value of derivative liability		—				475				—				(1,745	)
Change in fair value of contingent earn-out liability		7,245				32,609				9,754				32,609
Change in fair value of contingently issuable common stock liability		1,081				5,718				2,529				5,718
Change in fair value of public warrant liability		(1,146	)			3,152				4,297				3,152
Change in fair value of common stock warrant liability		—				42				—				(879	)
Total other income (expense), net	$	7,987			$	40,167			$	17,645			$	19,549
Net income (loss) attributable to common stockholders – basic	$	(18,615	)		$	20,807			$	(58,102	)		$	(15,676	)
Net income (loss) attributable to common stockholders – diluted	$	(18,615	)		$	21,278			$	(58,102	)		$	(15,676	)
Weighted average common shares outstanding
Basic		144,117,273				119,745,196				143,522,555				47,772,253
Diluted		144,117,273				153,936,436				143,522,555				47,772,253
Net income (loss) per share
Basic	$	(0.13	)		$	0.17			$	(0.40	)		$	(0.33	)
Diluted	$	(0.13	)		$	0.14			$	(0.40	)		$	(0.33	)
Net income (loss)	$	(18,615	)		$	20,807			$	(58,102	)		$	(15,676	)
Other comprehensive income (loss)
Cumulative translation adjustment		45				—		#		35		#		—
Total other comprehensive income		45				—				35				—
Total comprehensive income (loss)	$	(18,570	)		$	20,807			$	(58,067	)		$	(15,676	)

EVOLV TECHNOLOGY
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)

	September 30, 2022				December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	218,499			$	307,492
Restricted cash		400				400
Accounts receivable, net		21,199				6,477
Inventory		6,732				2,890
Current portion of contract assets		5,291				1,459
Current portion of commission asset		2,413				1,645
Prepaid expenses and other current assets		20,223				10,757
Total current assets		274,757				331,120
Restricted cash, noncurrent		275				275
Contract assets, noncurrent		1,524				3,418
Commission asset, noncurrent		4,607				3,719
Property and equipment, net		40,532				23,783
Operating lease right-of-use assets		1,882				—
Other assets		2,045				542
Total assets	$	325,622			$	362,857
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	11,139			$	6,045
Accrued expenses and other current liabilities		8,884				9,551
Current portion of deferred revenue		15,852				6,599
Current portion of deferred rent		—				135
Current portion of long-term debt		4,000				2,000
Current portion of operating lease liabilities		1,106				—
Total current liabilities		40,981				24,330
Deferred revenue, noncurrent		9,234				2,475
Deferred rent, noncurrent		—				333
Long-term debt, noncurrent		4,959				7,945
Operating lease liabilities, noncurrent		1,147				—
Contingent earn-out liability		11,452				21,206
Contingently issuable common stock liability		2,735				5,264
Public warrant liability		6,733				11,030
Total liabilities		77,241				72,583
Stockholders’ equity:
Preferred stock, $0.0001 par value; 100,000,000 authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021		—				—
Common stock, $0.0001 par value; 1,100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 144,434,717 and 142,745,021 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		14				14
Additional paid-in capital		412,238				396,064
Accumulated other comprehensive income		35				—
Accumulated deficit		(163,906	)			(105,804	)
Stockholders’ equity		248,381				290,274
Total liabilities and stockholders’ equity	$	325,622			$	362,857

EVOLV TECHNOLOGY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

	Nine Months Ended September 30,
		2022				2021
Cash flows from operating activities:
Net loss	$	(58,102	)		$	(15,676	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,782				1,948
Write-off of inventory		559				400
Adjustment to property and equipment for sales type leases		(625	)			—
Loss from impairment of property and equipment		1,038				1,656
Loss on disposal of property and equipment		—				659
Stock-based compensation		15,513				6,032
Non-cash interest expense		14				5,561
Non-cash lease expense		602				—
Provision recorded for allowance for doubtful accounts		100				(63	)
Loss on extinguishment of debt		—				12,685
Change in fair value of derivative liability		—				1,745
Change in fair value of common stock warrant liability		—				879
Change in fair value of earn-out liability		(9,754	)			(32,609	)
Change in fair value of contingently issuable common stock		(2,529	)			(5,718	)
Change in fair value of public warrant liability		(4,297	)			(3,152	)
Changes in operating assets and liabilities
Accounts receivable		(14,822	)			(5,866	)
Inventory		(4,401	)			(736	)
Commission assets		(1,656	)			(1,102	)
Contract assets		(1,938	)			(3,477	)
Other assets		(629	)			23
Prepaid expenses and other current assets		(9,009	)			(11,535	)
Accounts payable		2,177				240
Deferred revenue		16,005				2,352
Deferred rent		—				397
Warranty Reserve		—				(42	)
Accrued expenses and other current liabilities		(750	)			2,834
Operating lease liability		(699	)			—
Net cash used in operating activities		(69,421	)			(42,565	)
Cash flows from investing activities:
Development of internal-use software		(1,936	)			—
Purchases of property and equipment		(17,554	)			(10,994	)
Proceeds from sale of property and equipment		312				—
Net cash used in investing activities		(19,178	)			(10,994	)
Cash flows from financing activities:
Proceeds from exercise of stock options		571				777
Proceeds from issuance of common stock from the PIPE Investment		—				300,000
Proceeds from the closing of the Merger		—				84,945
Payment of offering costs from the closing of the Merger and PIPE Investment		—				(33,968	)
Repayment of financing obligations		—				(359	)
Proceeds from long-term debt, net of issuance costs		—				31,882
Repayment of principal on long-term debt		(1,000	)			—
Net cash provided by (used in) financing activities		(429	)			383,277
Effect of exchange rate changes on cash and cash equivalents		35				—
Net increase (decrease) in cash, cash equivalents and restricted cash		(88,993	)			329,718
Cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period		308,167				4,704
Cash, cash equivalents and restricted cash at end of period	$	219,174			$	334,422

EVOLV TECHNOLOGY
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS
(In thousands)
(Unaudited)

In preparing the condensed consolidated financial statements as of and for the three and six months ended June 30, 2022, the Company identified various errors in its previously issued financial statements. The identified errors impacted the Company's previously issued 2021 quarterly and annual financial statements and its quarterly financial statements for the three months ended March 31, 2022, and accordingly the Company has made adjustments to the prior period amounts presented herein. A summary of the revisions to certain previously reported financial information impacting amounts presented in this earnings release is as follows (in thousands):

	Three Months Ended September 30, 2021												Nine Months Ended September 30, 2021
	As Previously Reported				Adjustment				As Revised				As Previously Reported				Adjustment				As Revised
Revenue:
Product revenue	$	5,345			$	50			$	5,395			$	10,299			$	(20	)		$	10,279
Subscription revenue		2,305				7				2,312				5,118				(58	)			5,060
Service revenue		717				—				717				1,429				27				1,456
Total revenue		8,367				57				8,424				16,846				(51	)			16,795
Cost of revenue:
Cost of product revenue		2,933				34				2,967				7,237				149				7,386
Cost of subscription revenue		1,086				191				1,277				2,542				538				3,080
Cost of service revenue		192				521				713				732				953				1,685
Total cost of revenue		4,211				746				4,957				10,511				1,640				12,151
Gross profit		4,156				(689	)			3,467				6,335				(1,691	)			4,644
Operating expenses:
Research and development		3,641				(29	)			3,612				8,330				69				8,399
Sales and marketing expense		8,510				1,514				10,024				17,284				472				17,756
General and administrative		6,983				552				7,535				11,162				896				12,058
Loss from impairment of property and equipment		1,656				—				1,656				1,656				—				1,656
Total operating expenses		20,790				2,037				22,827				38,432				1,437				39,869
Loss from operations		(16,634	)			(2,726	)			(19,360	)			(32,097	)			(3,128	)			(35,225	)
Other income (expense), net:
Interest expense, net		(286	)			(9	)			(295	)			(5,988	)			36				(5,952	)
Other expense, net		(669	)			—				(669	)			(669	)			—				(669	)
Loss on extinguishment of debt		(865	)			—				(865	)			(12,685	)			—				(12,685	)
Change in fair value of derivative liability		475				—				475				(1,745	)			—				(1,745	)
Change in fair value of contingent earn-out liability		31,818				791				32,609				31,818				791				32,609
Change in fair value of contingently issuable common stock liability		5,718				—				5,718				5,718				—				5,718
Change in fair value of public warrant liability		3,152				—				3,152				3,152				—				3,152
Change in fair value of common stock warrant liability		42				—				42				(879	)			—				(879	)
Total other income (expense), net		39,385				782				40,167				18,722				827				19,549
Net income (loss) attributable to common stockholders - basic	$	22,751			$	(1,944	)		$	20,807			$	(13,375	)		$	(2,301	)		$	(15,676	)
Net income (loss) attributable to common stockholders - diluted	$	23,222			$	(1,944	)		$	21,278			$	(13,375	)		$	(2,301	)		$	(15,676	)

	December 31, 2021
	As Previously Reported			Adjustment			As Revised
Assets
Current assets:
Cash and cash equivalents	$	307,492		$	—		$	307,492
Restricted cash		400			—			400
Accounts receivable, net		6,477			—			6,477
Inventory		5,140			(2,250	)		2,890
Current portion of contract assets		1,459			—			1,459
Current portion of commission asset		1,645			—			1,645
Prepaid expenses and other current assets		11,047			(290	)		10,757
Total current assets		333,660			(2,540	)		331,120
Restricted cash, noncurrent		275			—			275
Contract assets, noncurrent		3,418			—			3,418
Commission asset, noncurrent		3,719			—			3,719
Property and equipment, net		21,592			2,191			23,783
Other assets		401			141			542
Total assets	$	363,065		$	(208	)	$	362,857
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	6,363		$	(318	)	$	6,045
Accrued expenses and other current liabilities		9,183			368			9,551
Current portion of deferred revenue		6,690			(91	)		6,599
Current portion of deferred rent		135			—			135
Current portion of long-term debt		2,000			—			2,000
Total current liabilities		24,371			(41	)		24,330
Deferred revenue, noncurrent		2,475			—			2,475
Deferred rent, noncurrent		333			—			333
Long-term debt, noncurrent		7,945			—			7,945
Contingent earn-out liability		20,809			397			21,206
Contingently issuable common stock liability		5,264			—			5,264
Public warrant liability		11,030			—			11,030
Total liabilities		72,227			356			72,583
Stockholders’ equity:
Convertible preferred stock		—			—			—
Common stock		14			—			14
Additional paid-in capital		395,563			501			396,064
Accumulated deficit		(104,739	)		(1,065	)		(105,804	)
Stockholders’ equity		290,838			(564	)		290,274
Total liabilities and stockholders’ equity	$	363,065		$	(208	)	$	362,857

EVOLV TECHNOLOGY
RECONCILIATION OF FORECASTED 2022 NET LOSS TO ADJUSTED EBITDA
(In thousands)
(Unaudited)

	Twelve Months Ended December 31, 2022
	High				Low
Net income (loss)	$	(76,000	)		$	(78,000	)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:
Depreciation and amortization		5,000				5,000
Stock-based compensation		19,000				19,000
Other one-time expenses		5,000				5,000
Other (income) expense		(18,000	)			(18,000	)
Adjusted EBITDA	$	(65,000	)		$	(67,000	)

EVOLV TECHNOLOGY
SUMMARY OF KEY OPERATING STATISTICS
(Unaudited)

	Three Months Ended or as of,
($ in thousands)		March 31, 2021				June 30, 2021				September 30, 2021				December 31, 2021				March 31, 2022				June 30, 2022				September 30, 2022
New customers			13				21				23				27				44				53				92
Total contract value of orders booked		$	8,424			$	10,476			$	16,995			$	17,916			$	19,167			$	22,066			$	45,353
Annual recurring revenue		$	5,424			$	7,423			$	9,932			$	12,907			$	16,641			$	20,865			$	28,741
Remaining performance obligation		$	17,658			$	24,930			$	34,152			$	51,430			$	63,750			$	80,978			$	109,407
Net additions			64				113				176				136				207				237				545
Ending deployed units			278				391				567				703				910				1,147				1,692

EVOLV TECHNOLOGY
RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES
(In thousands)
(Unaudited)

	Three Months Ended,
		March 31, 2021				June 30, 2021				September 30, 2021				December 31, 2021				March 31, 2022				June 30, 2022				September 30, 2022
Operating expenses, GAAP		$	9,400			$	7,642			$	22,826			$	19,429			$	24,760			$	25,835			$	26,827
Stock-based compensation(1)			(300	)			(1,052	)			(4,589	)			(3,513	)			(3,819	)			(4,781	)			(6,298	)
Restructuring expenses			—				—				—				—				(324	)			13				—
Loss on impairment of lease equipment			—				—				(1,656	)			(213	)			(96	)			(316	)			(626	)
Other one-time expenses			—				—				(685	)			—				(1,107	)			(2,298	)			(69	)
Adjusted Operating Expenses		$	9,100			$	6,590			$	15,896			$	15,703			$	19,414			$	18,453			$	19,834

(1) Reflects immaterial adjustments to previously reported stock-based compensation amounts.

EVOLV TECHNOLOGY
RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED GROSS PROFIT AND GAAP OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS)
(In thousands)
(Unaudited)

	Three Months Ended September 30,								Nine Months Ended September 30,
	2022				2021				2022				2021
Revenue	$	16,530			$	8,424			$	34,310			$	16,795
Cost of revenue		16,305				4,957				32,635				12,151
Gross Profit, GAAP		225				3,467				1,675				4,644
Stock-based compensation(2)		227				66				615				91
Amortization of capitalized stock-based compensation		6				—				15				—
Adjusted Gross Profit	$	458			$	3,533			$	2,305			$	4,735
Gross Margin %		1.4	%			41.2	%			4.9	%			27.7	%
Adjusted Gross Margin %		2.8	%			41.9	%			6.7	%			28.2	%

(2) Reflects immaterial adjustments to previously reported stock-based compensation amounts.

	Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Operating income (loss), GAAP	$	(26,602	)		$	(19,360	)		$	(75,747	)		$	(35,225	)
Stock-based compensation		6,525				4,655				15,513				6,032
Amortization of capitalized stock-based compensation		6				—				15				—
Restructuring expenses		—				—				311				—
Loss on impairment of lease equipment		626				1,656				1,038				1,656
Other one-time expenses		69				685				3,474				685
Adjusted Operating Income (loss)	$	(19,376	)		$	(12,364	)		$	(55,396	)		$	(26,852	)

EVOLV TECHNOLOGY
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(In thousands)
(Unaudited)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Net income (loss)	$	(18,615	)		$	20,807			$	(58,102	)		$	(15,676	)
Depreciation & amortization		1,432				846				3,782				1,948
Stock-based compensation		6,525				4,655				15,513				6,032
Interest expense (income)		(864	)			295				(1,122	)			5,952
Loss on disposal of property & equipment		—				659				—				659
Loss on extinguishment of debt		—				865				—				12,685
Change in fair value of derivative liability		—				(475	)			—				1,745
Change in fair value of contingent earn-out liability		(7,245	)			(32,609	)			(9,754	)			(32,609	)
Change in fair value of contingently issuable common stock liability		(1,081	)			(5,718	)			(2,529	)			(5,718	)
Change in fair value of public warrant liability		1,146				(3,152	)			(4,297	)			(3,152	)
Change in fair value of common stock warrant liability		—				(42	)			—				879
Restructuring expenses		—				—				311				—
Loss on impairment of lease equipment		626				1,656				1,038				1,656
Other one-time expenses		69				685				3,474				685
Adjusted EBITDA	$	(18,007	)		$	(11,528	)		$	(51,686	)		$	(24,914	)

EVOLV TECHNOLOGY
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EARNINGS (LOSS)
(In thousands, except share and per share data)
(Unaudited)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Net income (loss) attributable to common stockholders – diluted	$	(18,615	)		$	21,278			$	(58,102	)		$	(15,676	)
Stock-based compensation		6,525				4,655				15,513				6,032
Amortization of capitalized stock-based compensation		6				—				15				—
Loss on extinguishment of debt		—				865				—				12,685
Change in fair value of derivative liability		—				(475	)			—				1,745
Change in fair value of contingent earn-out liability		(7,245	)			(32,609	)			(9,754	)			(32,609	)
Change in fair value of contingently issuable common stock liability		(1,081	)			(5,718	)			(2,529	)			(5,718	)
Change in fair value of public warrant liability		1,146				(3,152	)			(4,297	)			(3,152	)
Change in fair value of common stock warrant liability		—				(42	)			—				879
Restructuring expenses		—				—				311				—
Loss on impairment of lease equipment		626				1,656				1,038				1,656
Other one-time expenses		69				685				3,474				685
Adjusted earnings (loss) attributable to common stockholders - diluted	$	(18,569	)		$	(12,857	)		$	(54,331	)		$	(33,473	)
Weighted average common shares outstanding – diluted		144,117,273				153,936,436				143,522,555				47,772,253
Adjusted Earnings Per Share – diluted	$	(0.13	)		$	(0.08	)		$	(0.38	)		$	(0.70	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005860/en/

Investor Relations:

Brian Norris

Vice President of Finance and Investor Relations

bnorris@evolvtechnology.com

Source: Evolv Technology

FAQ

What were Evolv Technology's Q3 2022 earnings results?

Evolv reported Q3 2022 revenues of $16.5 million, a 96% increase year-over-year.

What is Evolv's updated revenue outlook for 2022?

Evolv raised its 2022 revenue outlook to $46-$48 million.

What is Evolv Technology's expected ARR for 2023?

Evolv anticipates exiting 2023 with an ARR between $65 million and $70 million.

How did Evolv Technology's net loss change in Q3 2022?

Evolv reported a net loss of $(18.6) million in Q3 2022, which increased from $(12.9) million in Q3 2021.